In the last trading session, 10.79 million shares of the Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) were traded, and its beta was 0.63. Most recently the company’s share price was $16.63, and it changed around -$0.22 or -1.31% from the last close, which brings the market valuation of the company to $19.07B. TEVA currently trades at a discount to its 52-week high of $22.80, offering almost -37.1% off that amount. The share price’s 52-week low was $12.47, which indicates that the current value has risen by an impressive 25.02% since then. We note from Teva- Pharmaceutical Industries Ltd. ADR’s average daily trading volume that its 10-day average is 9.61 million shares, with the 3-month average coming to 12.03 million.
Teva- Pharmaceutical Industries Ltd. ADR stock received a consensus recommendation rating of Buy, based on a mean score of 1.40. If we narrow it down even further, the data shows that 0 out of 12 analysts rate the stock as a Sell; another 4 rate it as Overweight. Among the rest, 1 recommended TEVA as a Hold, whereas 7 deemed it a Buy, and 0 rated it as Underweight. Teva- Pharmaceutical Industries Ltd. ADR is expected to report earnings per share of 0.64 for the current quarter.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) trade information
Instantly TEVA has showed a red trend with a performance of -1.31% at the end of last trading. The performance over the last five days has remained in the red territory. The rise to weekly highs of 17.30 on recent trading dayincreased the stock’s daily price by 3.87%. The company’s shares are currently down -1.13% year-to-date, but still down -0.78% over the last five days. On the other hand, Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA) is -3.59% down in the 30-day period. We can see from the shorts that 40.0 million shares have been sold at a short interest cover period of 3.61 day(s).
The consensus price target as assigned by Wall Street analysts is $22, which translates to bulls needing to increase their stock price by 24.41% from its current value. Analyst projections state that TEVA is forecast to be at a low of $10 and a high of $28.
Teva- Pharmaceutical Industries Ltd. ADR (TEVA) estimates and forecasts
The year-over-year growth rate is expected to be 2.55%, up from the previous year.
Consensus estimates provided by 7 financial analysts predict the company will bring in an average of 4.3B in revenue for the current quarter. 7 analysts expect Teva- Pharmaceutical Industries Ltd. ADR to make 4.45B in revenue for the current ending quarter. The company’s sales for the same quarters a year ago were 4.16B and 4.33B respectively. Analysts predict that the company’s current quarter sales will jump, forecast at 3.16%. Forecasts for the next quarter put sales growth at 2.77%.
Looking at the company’s year-over-year earnings, the past five years showed a negative earnings growth rate of -9.62%. Teva- Pharmaceutical Industries Ltd. ADR earnings are expected to increase by 2.13% in 2025, but the outlook is positive 7.70% per year for the next five years.
TEVA Dividends
Teva- Pharmaceutical Industries Ltd. ADR’s next quarterly earnings report is expected to be released on 2025-May-07. The average dividend yield for the past five years averaged 2.95 per year.
Teva- Pharmaceutical Industries Ltd. ADR (NYSE:TEVA)’s Major holders
Upon looking at major shareholders, it appears that insiders hold 0.00% of Teva- Pharmaceutical Industries Ltd. ADR shares, and 64.52% of them are in the hands of institutional investors. The stock currently has a share float of 64.52%. Teva- Pharmaceutical Industries Ltd. ADR stock is held by 750.0 institutions, with BLACKROCK INC. being the largest institutional investor. By 2024-06-30, it held 3.7942% of the shares, which is about 42.99 million shares worth $698.55 million.
FMR LLC, with 3.7051% or 41.98 million shares worth $682.15 million as of 2024-06-30, holds the second largest percentage of outstanding shares.
Fidelity Contrafund and iShares Trust-iShares Core MSCI EAFE ETF were the top two Mutual Funds as of May 31, 2025 . The former held 17.36 shares worth $288.65 million, making up 1.51% of all outstanding shares. On the other hand, iShares Trust-iShares Core MSCI EAFE ETF held roughly 7.36 shares worth around $122.47 million, which represents about 0.64% of the total shares outstanding.
